Clinical trials: Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome
Lymphoma
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00369629
- Testing
- Gemcitabine, Pemetrexed
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Sezary Syndrome, Mycosis Fungoides
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS.
- Trial name
- NCT04256018
- Testing
- Mogamulizumab, LD TSEBT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome that has come back (relapsed) or has not responded to previous treatment…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome
- Trial name
- NCT03063632
- Testing
- Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous T-Cell Lymphoma
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
- Trial name
- NCT00425555
- Testing
- Panobinostat
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab.
- Conditions
- Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Sezary Syndrome
- Trial name
- NCT07003100
- Testing
- Non-Interventional Study
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- City of Hope Medical Center
Cutaneous T-cell Lymphoma
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
The goal of this clinical research study is to learn if treatment with curcumin can help to decrease the size of lesions and/or decrease itching in patients with MF or SS. The safety of curcumin will also be studied.
- Trial name
- NCT00969085
- Testing
- Curcumin (Turmeric), Questionnaires, Photos
- Sponsor
- M.D. Anderson Cancer Center
Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome (MF/SS), n=12, or b) T-cell large granular…
- Trial name
- GEMSTONE (NCT07682792)
- Testing
- Golidocitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
In the proposed study, NM-IL-12 will be evaluated as immunotherapy to increase antitumor efficacy against CTCL, while reducing skin-related toxicity, when combined with low-dose TSEBT therapy.
- Conditions
- Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sézary Syndrome
- Trial name
- NCT02542124
- Testing
- NM-IL-12 and TSEBT
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neumedicines Inc.
Mycosis Fungoides, Non-Hodgkin's Lymphoma
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions.
- Trial name
- NCT02848274
- Where
- 13 sites in United States, Argentina and 5 more
- Volunteers
- 2,000 people
- Sponsor
- Stanford University
Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS).
- Conditions
- Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides
- Trial name
- NCT01396070
- Testing
- Brentuximab vedotin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Youn Kim
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
- Conditions
- Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
- Trial name
- FIL_CTCL (NCT06588868)
- Where
- 18 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
This phase Ib/II trial investigates the side effects of mogamulizumab and extracorporeal photopheresis and to see how well they work in treating patients with Sezary syndrome or mycosis fungoides.
- Conditions
- Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
- Trial name
- NCT04676087
- Testing
- Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Cutaneous T-Cell Lymphoma
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy
- Trial name
- NCT06285370
- Testing
- Mogamulizumab
- Where
- 8 sites in China
- Volunteers
- 23 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Mycosis Fungoides, Sezary Syndrome
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have recently achieved disease control…
- Conditions
- Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous
- Trial name
- RESMAIN (NCT02953301)
- Testing
- resminostat
- Where
- 54 sites in Austria, Belgium and 10 more
- Volunteers
- 201 people
- Sponsor
- 4SC AG
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
- Conditions
- Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary
- Trial name
- NCT04960618
- Testing
- Gemcitabine, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome.
- Conditions
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
- Trial name
- NCT04652960
- Testing
- Biospecimen Collection, Computed Tomography, Duvelisib
- Where
- 17 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Mycosis Fungoides/Sezary Syndrome, Cutaneous T Cell Lymphoma
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Cutaneous T-cell lymphomas (CTCL) are a group of primary cutaneous lymphomas including Mycosis Fungoides (MF) and Sézary syndrome (SS).
- Trial name
- KISS01 (NCT06651203)
- Testing
- Follow-up
- Volunteers
- 460 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mycosis Fungoides, Sezary Syndrome
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
A translational study for identification of prognostic and treatment-predictive biomarkers in Mycosis fungoides and Sézary syndrome.
- Trial name
- BIO-MUSE (NCT04904146)
- Testing
- Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Lund University Hospital
Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome
A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Patients with relapsed or refractory cutaneous T-cell lymphoma (R/R CTCL) face a poor prognosis and limited therapeutic options. Advanced or relapsed disease yields a 5-year overall survival rate of <50%.
- Trial name
- NCT07854639
- Testing
- Zeprumetostat Tablets
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University First Hospital
Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis…
- Conditions
- Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
- Trial name
- NCT02811783
- Testing
- Naloxone Hydrochloride Lotion, 0.5%
- Where
- 16 sites in United States
- Volunteers
- 59 people
- Sponsor
- Elorac, Inc.